Active vibration isolation system (AVIS) using the traditional vibration isolation technology, such as reducing suspending stiffness and adding absolute damping, has performance defects due to the residual low-frequency disturbances which still severely restrict the precision machine accuracy. This paper proposes a novel vibration control method combining inertial absolute sensor feedback (ASF) and positive relative sensor feedback (RSF), which can highly improve the low-frequency vibration isolation performance, and the blending control method is analyzed according to the vibration transmission. The results show that ASF strengthens the connection between the payload and the absolute space, while positive RSF weakens the connection between the payload and the base. By introducing ASF and positive RSF blended, the stiffness and damping between the payload and the absolute space can be increased to near infinity, while the stiffness and damping between the payload and the base can be attenuated to near zero. The blending control method includes absolute displacement feedback (ADF), positive relative displacement feedback (RDF), absolute velocity feedback (AVF), and positive relative velocity feedback (RVF). ADF combined with RDF improves the vibration isolation performance at low-frequency, while AVF combined with RVF improves the performance around the inherent frequency and high-frequency. In this way, the payload is hard to be affected by disturbances in a broad frequency region. Finally, the proposed method is verified by experiments and compared with the commonly used sky-hook damping method. It shows that the initial frequency of vibration isolation is reduced from 5.6 Hz (sky-hook damping method) to 1 Hz (the proposed method), the magnitude of vibration transmission starts with −11.1 dB (at 1 HZ), and the maximum magnitude is always below 0 dB from 1 Hz to 50 Hz.

Anthracycline is a first-line chemotherapy drug used to treat childhood acute leukemia, which may cause cardiac toxicity including common arrhythmia, valve disease, pericardial effusion, and even rare cardiomyopathy and cardiac failure. We reported a 2-year-old boy who was treated irregularly for acute lymphoblastic leukemia with daunorubicin. After 26 months, his left ventricular ejection fraction decreased to 40% and progressively decreased to 20–30%. Then he successfully received a heart transplant and the myocardium was confirmed with dilated cardiomyopathy. Eight months after cardiac transplantation, he was admitted again for left neck mass and was diagnosed with monomorphic diffuse large B cell lymphoma associated with Epstein-Barr virus infection by biopsy. We present this case to highlight the importance of standard chemotherapy of daunorubicin, clinical prevention, and monitoring of anthracycline-induced cardiotoxicity in acute lymphoblastic leukemia children to ensure their good prognosis and long-term life quality.